Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Sigmoid Adenocarcinoma with Regional Scrotal Metastasis.

Swofford BP, Dragovich T.

Case Rep Oncol. 2017 May 5;10(2):416-419. doi: 10.1159/000474936. eCollection 2017 May-Aug.

2.

Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas.

Elquza E, Babiker HM, Howell KJ, Kovoor AI, Brown TD, Patel H, Malangone SA, Borad MJ, Dragovich T.

Cancer Invest. 2016;34(2):57-63. doi: 10.3109/07357907.2015.1108426. Epub 2016 Jan 25.

PMID:
26810581
3.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group.

Lancet. 2016 Feb 6;387(10018):545-57. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in: Lancet. 2016 Feb 6;387(10018):536.

PMID:
26615328
4.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD.

Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.

5.

Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications.

Chang J, Schomer D, Dragovich T.

Biomed Res Int. 2015;2015:269641. doi: 10.1155/2015/269641. Epub 2015 Jun 4. Review.

6.

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.

Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP.

J Clin Oncol. 2015 May 1;33(13):1475-81. doi: 10.1200/JCO.2014.55.7504. Epub 2014 Dec 15.

7.

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.

Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein PJ, Rolfe L, Saif MW, LaValle J, Yu KH, Lowery MA, Allen A, O'Reilly EM.

Pancreatology. 2014 Sep-Oct;14(5):398-402. doi: 10.1016/j.pan.2014.07.003. Epub 2014 Jul 18.

8.

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD.

Cancer Chemother Pharmacol. 2014 Aug;74(2):379-87. doi: 10.1007/s00280-014-2499-4. Epub 2014 Jun 18.

9.

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.

Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D.

Cancer Chemother Pharmacol. 2013 May;71(5):1345-55. doi: 10.1007/s00280-013-2134-9. Epub 2013 Apr 6.

PMID:
23564374
10.

A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.

Baker AF, Adab KN, Raghunand N, Chow HH, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T.

Invest New Drugs. 2013 Jun;31(3):631-41. doi: 10.1007/s10637-012-9846-2. Epub 2012 Jun 19.

11.

Is there a case for personalized therapy of pancreatic cancer?

Dragovich T.

Clin Adv Hematol Oncol. 2012 May;10(5):344-5. Review. No abstract available.

PMID:
22706549
12.

Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques.

Rajaraman S, Rodriguez JJ, Graff C, Altbach MI, Dragovich T, Sirlin CB, Korn RL, Raghunand N.

Magn Reson Imaging. 2011 Jun;29(5):668-82. doi: 10.1016/j.mri.2011.02.012. Epub 2011 Apr 29.

13.

Management strategies in pancreatic cancer.

Campen CJ, Dragovich T, Baker AF.

Am J Health Syst Pharm. 2011 Apr 1;68(7):573-84. doi: 10.2146/ajhp100254. Review.

PMID:
21411798
14.

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.

Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H.

Ann Oncol. 2011 Sep;22(9):2137-43. doi: 10.1093/annonc/mdq734. Epub 2011 Feb 16.

PMID:
21325451
15.

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.

Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD.

Cancer Chemother Pharmacol. 2011 Mar;67(3):503-9. doi: 10.1007/s00280-010-1343-8. Epub 2010 May 12.

PMID:
20461382
16.

A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma.

Chiorean EG, Dragovich T, Hamm J, Barrios CH, Gorini CF, Langmuir VK, Kroll S, Jung DT, Tidmarsh GT, Loehrer PJ.

Am J Clin Oncol. 2010 Apr;33(2):111-6. doi: 10.1097/COC.0b013e3181979204.

PMID:
19687729
17.

Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept.

Dragovich T, Campen C.

J Oncol. 2009;2009:804108. doi: 10.1155/2009/804108. Epub 2009 Jul 14.

18.
20.

Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.

Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ.

J Clin Oncol. 2008 May 10;26(14):2320-6. doi: 10.1200/JCO.2007.14.0152.

PMID:
18467723

Supplemental Content

Loading ...
Support Center